Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 79 results for "lacosamide"

Enquiry//Lacosamide, Rivaroxaban, Abiraterone Acetate & other ...

20 Dec 2016 An organization based in Mumbai, India, which was established over a decade ago to cater to the needs of pharmaceutical companies is searching for suppliers of 10-15kg of Abiraterone Acetate for Argentina and 1-2kg for R&D ... PharmaCompass, 1 month ago

5 images for lacosamide

Edu Bourse, 1 month ago
Pharmaceutical Journal, 1 month ago, 6 months ago
Pharmafile, 6 months ago
Edu Bourse, 6 months ago
Edu Bourse

BRIEF-UCB announces EU approval for Vimpat as monotherapy

n"Dec 20 UCB SA :* * Vimpat EU monotherapy approval * European commission approved license extension for Vimpat (lacosamide) for use as monotherapy in treatment of partial-onset seizures in adult and adolescent patients with epilepsy * Approval ...
 Reuters UK1 month ago UCB's anti-epileptic drug VIMPAT (lacosamide) approved as monotherapy by European Commission  FirstWord Pharma1 month ago UCB's anti-epileptic drug VIMPAT® (lacosamide) approved as monotherapy by European Commission  Edu Bourse1 month ago

2 Minute Medicine Rewind November 28, 2016

Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy Epilepsy affects approximately 65 million people worldwide, and 1 in 26 people will develop epilepsy in ...
 2 Minute Medicine1 month ago Lacosamide Monotherapy Effective in Elderly Patients With Newly Diagnosed Epilepsy: Presented at AES  FirstWord Pharma1 month ago Support for lacosamide as a monotherapy in newly diagnosed epilepsy  MedWire News1 month ago

Adamas Pharma Completes Phase I Clinical Trial Of ADS-4101 For Treatment Of Partial Onset Seizures In Patients With Epilepsy

- ADS-4101 is a chrono-synchronous lacosamide, designed to deliver high concentrations of medicine during the day when seizures primarily occur EMERYVILLE, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS ) ...
 BioSpace2 weeks ago Adamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy  BizWire Express2 weeks ago Adamas Outlines Key 2017 Priorities and Highlights 2016 Achievements  TeleTrader.com2 weeks ago

UCB highlights epilepsy research at the 2016 American Epilepsy Society Annual Meeting

BRUSSELS Data being presented include posters further describing the safety and efficacy profile of VIMPAT® (lacosamide) CV and BRIVIACT® (brivaracetam) CV.2,3,4,6,8 Presentations will also share findings on the current state of the union of ...
 Bio-Medicine1 month ago

Global Epilepsy Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

World News: 15:26 GMT Tuesday 20th December 2016. [Research and Markets via Globe Newswire via SPi World News] Dublin, Dec. 20, 2016 (GLOBE NEWSWIRE) -- has announced the addition of the report to their offering. Refractory patients, niche ...
 SPi World News1 month ago

European Commission Grants Marketing Authorisation for Zebinix® (eslicarbazepine acetate) for the Treatment of Partial-Onset Seizures in Children

The European Commission extended the Marketing Authorisation for Zebinix® (eslicarbazepine acetate) as a once-daily adjunctive treatment for patients aged above six years with partial-onset (focal) seizures with or without secondary ...
 Wallstreet Online1 month ago Nuevos datos de Zebinix® (acetato de eslicarbazepina), administrado una vez al día como terapia adyuvante, muestran buen control de las crisis y tolerabilidad en personas con crisis (focales) de inicio parcial  BioMedReports1 month ago

Lamotrigine, Levetiracetam Top AEDs in Pregnancy

HOUSTON — Patterns of antiepileptic drug (AED) prescriptions for patients during pregnancy have changed dramatically over the past 15 years, at least at tertiary centers in the United States, new research shows. At the turn of the last century, ...
 Dermatology Online Journal1 month ago

New Data for Once-​daily Adjunctive Zebinix® (eslicarbazepine acetate) Show Good Seizure Control and Tolerability in People With Partial Onset (Focal) Seizures

/PRNewswire/ -- FOR EMEA MEDIA ONLY - NOT FOR SWISS/AUSTRIAN/US JOURNALISTS Zebinix® (eslicarbazepine acetate) provides a high retention rate, reduction in seizure frequency and seizure freedom with a favourable adverse event profile and an ...
 Ariva.de1 month ago New Data for Once-daily Adjunctive Zebinix® (eslicarbazepine acetate) Show Good Seizure Control and Tolerability in People With Partial Onset (Focal) Seizures  PharmiWeb1 month ago

Les nouvelles données du traitement en association de Zebinix® (acétate d'eslicarbazépine) en monoprise quotidienne démontrent un contrôle des crises et un rapport efficacité/tolérance favorable chez les personnes souffrant de crises partielles d'

Selon l'étude ESLADOBA présentée aujourd'hui lors du congrès annuel de l'American Epilepsy Society (AES) à Houston , aux États-Unis, le Zebinix ® (acétate d'eslicarbazépine) entraîne un taux de rétention élevé, une réduction de la ...
 BioMedReports1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less